Home › Chronic Lymphocytic Leukemia › Washington
Chronic Lymphocytic Leukemia clinical trials in Washington
27 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Washington.
Cities in Washington
- Seattle22 studies
- Spokane6 studies
- Tacoma5 studies
- Kirkland4 studies
- Renton3 studies
- Spokane Valley3 studies
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- FHCC Overlake, Bellevue
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04269902ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Medical Oncology Associates - Spokane, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07342478A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Vista Oncology ( Site 5449), Olympia
- Medical Oncology Associates, PS ( Site 5406), Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05947851Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- and 20 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Nov 3, 2026 · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07221500Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06839053A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 30, 2026 · NCT06520098Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07194980A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06697184Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT04941716A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Swedish Medical Center Swedish Cancer Institute First Hill Campus, Seattle
- Northwest Cancer Specialist, Pc(Us Oncology Research), Vancouver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06943872A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Fred Hutch Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06528301Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07648264A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Swedish Cancer Institute, Edmonds Campus ( Site 0072), Edmonds
- Swedish Cancer Institute, Issaquah Campus ( Site 0073), Issaquah
- Swedish Medical Center-Swedish Cancer Institute ( Site 0071), Seattle
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 103, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07582432A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Fred Hutchinson Cancer Research Center, Seattle
- Summit Cancer Centers, Spokane
- Northwest Medical Specialties, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Medical Oncology Associates, PS, Spokane
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Vista Oncology - East Olympia /ID# 267337, Olympia
- Northwest Medical Specialties Tacoma /ID# 266327, Tacoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06428019A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Swedish Cancer Institute, Seattle
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Swedish Cancer Institute, Seattle
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.